Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04712097 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04712097 · ClinicalTrials.gov record · last posted 2026-07-10

A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma

Study acronym: Celestimo
StatusActive, Not Recruiting
PhasePhase 3
Started2021-10-27
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This study will evaluate the efficacy and safety of mosunetuzumab in combination with lenalidomide (M + Len) compared to rituximab in combination with lenalidomide (R + Len) in participants with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least one line of prior systemic therapy.

Protocol amendment history 1 change detected by DataLookout

2026-05-06
Primary completion pushed: 2026-05-31 → 2026-06-30
Trial Details
NCT Number NCT04712097
Lead Sponsor Hoffmann-La Roche
Conditions Relapsed or Refractory Follicular Lymphoma
Enrollment 478 participants
Start Date 2021-10-27
Primary Completion 2026-06-03 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-10